Bruenger F W, Lloyd R D, Miller S C
Radiobiology Division, School of Medicine, University of Utah, Salt Lake City 84112.
Radiat Res. 1991 Mar;125(3):248-56.
The influence of age at injection of 226Ra or 239Pu on skeletal deposition and local distribution, the pattern of bone tumor formation, and postinjection survival was assessed in parallel short-term studies of mechanisms and lifetime toxicity. Beagles received a single intravenous injection of 226Ra or 239Pu at 3 months (juveniles), 17-19 months (young adults) or 60 months (mature). Data from short-term studies of mechanisms and dosimetry and from one dosage level (41 kBq 226Ra/kg or 11 kBq 239Pu/kg body mass) of each of the toxicity experiments were compared. Skeletal growth and turnover produced differential initial deposition and distribution patterns typical for each age group. At 1 week after injection, skeletal retention of 226Ra or 239Pu was 68 and 68%, respectively, in the juveniles, 32 and 46% in the young adults, and 31 and 43% in the mature dogs. Comparing individual bones in the juveniles, gradients in the concentration of 239Pu were small since all bones were actively growing, but substantial gradients, corresponding to centers of ossification, were present within individual bones. In other age groups, local concentration gradients were less pronounced, but much larger differences were present among the various bones. In the toxicity study all animals injected with either 41 kBq 226Ra/kg or 11 kBq 239Pu/kg have died. The cumulative average skeletal doses to the presumed time of start of tumor growth (1 year before death) were 25 and 4 Gy, respectively, for the juveniles, 22 and 5 Gy for the young adults, and 15 and 4 Gy for the mature dogs. The highest bone tumor incidence was seen in the young adult groups. Differences were observed in location of bone tumors between dogs in the same age group given radium or plutonium and among age groups injected with either radionuclide, some of which could be explained by differences in local dose distributions. Median postinjection survival assessed by the Kaplan-Meier nonparametric method ranged from 2513 and 2592 days for the juveniles to 2099 and 1617 for the young adults to 2086 and 1421 in the mature groups. Cox regression analysis indicated no significant differences in postinjection survivals (uncorrected for the different preinjection periods) of groups injected with radium, but there was a statistically significant difference among the groups injected with plutonium. It was demonstrated that differences in the effects of 239Pu in the three groups were due primarily to the age- and time-dependent local distribution of the radionuclide.
在关于机制和终生毒性的平行短期研究中,评估了注射226镭或239钚时的年龄对骨骼沉积和局部分布、骨肿瘤形成模式以及注射后存活情况的影响。比格犬在3个月(幼年)、17 - 19个月(青年)或60个月(成年)时接受单次静脉注射226镭或239钚。比较了机制和剂量学短期研究的数据以及每个毒性实验一个剂量水平(41 kBq 226镭/千克或11 kBq 239钚/千克体重)的数据。骨骼生长和更新产生了每个年龄组典型的不同初始沉积和分布模式。注射后1周,幼年比格犬体内226镭或239钚的骨骼保留率分别为68%和68%,青年为32%和46%,成年为31%和43%。比较幼年比格犬的各个骨骼,239钚浓度梯度较小,因为所有骨骼都在活跃生长,但在单个骨骼内存在与骨化中心相对应的显著梯度。在其他年龄组中,局部浓度梯度不太明显,但不同骨骼之间的差异要大得多。在毒性研究中,所有注射41 kBq 226镭/千克或11 kBq 239钚/千克的动物均已死亡。到假定肿瘤开始生长时间(死亡前1年)的累积平均骨骼剂量,幼年比格犬分别为25 Gy和4 Gy,青年为22 Gy和5 Gy,成年为15 Gy和4 Gy。骨肿瘤发病率最高的是青年组。在接受镭或钚注射的同一年龄组犬之间以及注射任一放射性核素的不同年龄组之间,观察到骨肿瘤位置存在差异,其中一些差异可以用局部剂量分布的不同来解释。通过Kaplan - Meier非参数方法评估的注射后中位存活时间,幼年组为2513天和2592天,青年组为2099天和1617天,成年组为2086天和1421天。Cox回归分析表明,注射镭的组之间注射后存活情况(未校正注射前不同时期)无显著差异,但注射钚的组之间存在统计学显著差异。结果表明,三组中239钚效应的差异主要归因于放射性核素随年龄和时间变化的局部分布。